Loading...
SRCL logo

Stericycle, Inc.NasdaqGS:SRCL 株式レポート

時価総額 US$5.8b
株価
n/a
US$61.81
該当なし内在価値ディスカウント
1Y50.9%
7D1.8%
1D
ポートフォリオ価値
​
表示

Stericycle, Inc.

NasdaqGS:SRCL 株式レポート

時価総額：US$5.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stericycle（SRCL）株式概要

ステリサイクル社は、その子会社とともに、米国、欧州、および国際的に規制廃棄物およびコンプライアンスサービスを提供している。 詳細

SRCL ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長3/6
過去の実績2/6
財務の健全性2/6
配当金0/6

報酬

当社が推定した公正価値より36.9%で取引されている

収益は年間42.41%増加すると予測されています

今年は黒字化を達成

リスク分析

利払いは収益で十分にカバーされない

財務結果に影響を与える大きな一時的項目


SRCL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Stericycle, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Stericycle
過去の株価
現在の株価US$61.98
52週高値US$61.99
52週安値US$40.47
ベータ1.11
1ヶ月の変化1.61%
3ヶ月変化6.29%
1年変化50.88%
3年間の変化0.75%
5年間の変化0.27%
IPOからの変化2,580.22%

最新ニュース

Seeking Alpha • Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Stericycle: Watch Potential Revenue Recovery And Margin Improvement

Summary SRCL's Q1 2024 operating margins beat expectations, and the company's EBITDA margin is expected to improve significantly for full-year 2024. I anticipate that Stericycle's Secure Information Destruction segment can realize a turnaround due to a more favorable base for YoY comparison in 2H and the introduction of a subscription service. My Buy rating for SRCL stays intact following an assessment of its outlook and valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 03

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Summary Stericycle's normalized EPS grew by +26% QoQ in Q4 2023, and this translated into a +14% bottom line beat. The company is anticipating that its earnings will expand strongly by +24% in this new fiscal year, which is better than what Wall Street had anticipated earlier. I stick to a Buy investment rating for Stericycle stock, as I have greater confidence in SRCL's long-term prospects after reviewing its Q4 results and 2024 guidance. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Stericycle: Muted Outlook, Fair Valuations

Summary Stericycle's revenue outlook is murky, the recovery for the secure information destruction business is still in progress, but the regulated waste and compliance segment might be affected by staffing shortages. SRCL should still record lower earnings for FY 2022 vis-a-vis FY 2021 despite delivering an EPS beat in Q2, due to higher operating and interest expenses. I continue to assign a Hold rating to Stericycle, as its valuations are reasonably fair and aligned with its full-year outlook. Elevator Pitch I rate Stericycle, Inc.'s (SRCL) stock as a Hold. I evaluated SRCL's pace of recovery from the pandemic and its capital allocation plans in an earlier October 22, 2021 article for the stock. I focus on the near-term expectations for Stericycle in this update. My analysis leads me to the conclusion that the consensus earnings forecasts implying a mid-single digit percentage decline for SRCL in FY 2022 are realistic, and Stericycle's current valuations seem to be fair taking into account the full-year outlook. As such, I maintain a Hold rating for SRCL. Revisions To Consensus Estimates The recent changes to the sell-side's consensus bottom line forecasts for Stericycle provide an indication of what the market expects of SRCL's future performance. The consensus Q3 2022 normalized earnings per share or EPS for SRCL has been revised upwards by a substantial +11% in the past one month. It is reasonable to assume that the Wall Street analysts had raised their third-quarter bottom line projections for the company in response to Stericycle's +9% EPS beat for Q2 2022. It is worthy of note that SRCL has had earnings misses for the prior four quarters between Q2 2021 and Q1 2022. But the full-year fiscal 2022 consensus numbers tell a different story. In the last one month, the market's consensus FY 2022 normalized EPS estimate ($2.06) for Stericycle has in fact been reduced slightly by -0.5%, notwithstanding SRCL's second-quarter earnings beat. Moreover, four of the eight analysts covering SRCL's shares actually lowered their EPS estimates for the company in the past month. The analysts' less than favorable view of Stericycle's full-year FY 2022 outlook might be linked to the company's most recently updated management guidance. At its Q2 2022 earnings call in early-August 2022, SRCL increased the mid-point of its FY 2022 revenue growth guidance from +4% to +5%, but it lowered the mid-point of its full-year EPS guidance from $2.15 to $2.075 (implying a -5% decline as compared to 2021 EPS of $2.19). In the rest of the article, I will assess the growth prospects of its two key business segment and the company's overall profitability. This will help to explain why company management and analysts are of the opinion that Stericycle's bottom line for FY 2022 will still contract despite above-expectations Q2 2022 earnings. Secure Information Destruction Business Performed Well in Q2 Organic revenue for Stericycle's secure information destruction business, adjusted to exclude inorganic transactions and foreign exchange effects, expanded by an impressive +12.2% YoY for the second quarter of 2022. The expectations for SRCL's secure information destruction segment weren't high, as this business faces structural challenges relating to reduced paper usage in an increasingly digitalized world. However, the company's business secure information destruction business has witnessed a meaningful recovery in Q2 2022, as pandemic restrictions are eased and an increasing number of workers return to offices. More critically, the current recovery for the secure information destruction segment still has legs to run. Stericycle highlighted at its second-quarter results briefing that "I don't think the industry has settled yet in terms of everybody being back to what is the new normal." In other words, SRCL is implying that there could be a further acceleration in the pace of people going back to offices in time to come, and this will be positive for the secure information destruction business' near-term outlook. Disappointing Performance For Regulated Waste And Compliance Services Segment In contrast with the double-digit top line growth for the secure information destruction segment in the recent quarter, Stericycle's other segment, the regulated waste and compliance services business disappointed investors with its Q2 2022 results. Specifically, the regulated waste and compliance services segment saw a very modest +1.8% YoY increase in its second-quarter organic revenue. Notably, SRCL mentioned at its Q2 2022 earnings briefing that "most of the growth" for the company's regulated waste and compliance services segment for the most recent quarter "was due to pricing." This suggests that volumes for this business was probably flattish on a YoY basis in the second quarter of this year. There are two key factors that explain why the regulated waste and compliance services business' volumes haven't grown in a meaningful way in the recent quarter. Firstly, there was a decline in COVID-19 testing and vaccinations in Q2, as COVID-19 transitions gradually into an endemic state. Secondly, the labor crunch has also affected the healthcare industry, which means that it is tough for the number of elective surgeries to return to similar levels seen before the pandemic anytime soon. Future Profitability Hurt By Operating Cost Pressures And Higher Interest Rates As discussed in an earlier section of the article, Stericycle cut its full-year FY 2022 bottom line guidance after it reported its Q2 2022 earnings. SRCL attributed this change to "higher cash operating and interest expenses" at its most recent quarterly investor call.
Seeking Alpha • Aug 04

Stericycle Q2 2022 Earnings Preview

Stericycle (NASDAQ:SRCL) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.44 (-34.3% Y/Y) and the consensus Revenue Estimate is $678.27M (+0.8% Y/Y). Over the last 2 years, SRCL has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 2 upward revisions and 1 downward.
Seeking Alpha • Jun 03

Stericycle: The Risks Outweigh The Reward

Stericycle seems to be in a continued state of decline, even though the pandemic is largely over. If shares were cheap enough, the company might be worth the risk, but that isn't the case either. Add in regulatory risks moving forward, and it's not worth the risk playing this name right now.
Seeking Alpha • Oct 22

Stericycle: A Neutral View

I am negative on SRCL's recovery prospects in the short term, as there has been a delay in the return of workers back to office. But I have a favorable opinion of Stericycle's capital allocation initiatives in relation to debt reduction and business or asset sales. Stericycle currently trades at consensus forward FY 2021 and FY 2022 normalized P/E multiples of 26.9 times and 25.2 times, respectively, and this seems expensive.
Seeking Alpha • Aug 08

Stericycle: A Successful Turnaround Is Likely

Revenues declined in 2018, 2019, and 2020 as the company is divesting some businesses. Long-term debt has dramatically declined in recent quarters. The company is highly profitable. Shares are down by ~55% from all-time highs in 2015. This is a turnaround play worth the risk at this price.

株主還元

SRCLUS Commercial ServicesUS 市場
7D1.8%1.2%1.1%
1Y50.9%-14.8%28.7%

業界別リターン: SRCL過去 1 年間で-14.8 % の収益を上げたUS Commercial Services業界を上回りました。

リターン対市場: SRCL過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。

価格変動

Is SRCL's price volatile compared to industry and market?
SRCL volatility
SRCL Average Weekly Movement1.4%
Commercial Services Industry Average Movement7.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

安定した株価: SRCL 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: SRCLの 週次ボラティリティ ( 1% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
198913,298Cindy Millerwww.stericycle.com

ステリサイクル社は、その子会社とともに、規制廃棄物およびコンプライアンスサービスを米国、欧州、および国際的に提供している。同社は、規制医療廃棄物、シャープス廃棄物管理・処分、医薬品廃棄物管理・処分、化学療法廃棄物・処分、規制薬物廃棄物処分、ヘルスケア有害廃棄物、統合廃棄物ストリームソリューションなどの規制廃棄物およびコンプライアンスサービス、メドドロップ薬物回収キオスク、セーフコミュニティソリューション、セーフドロップシャープスメールバックソリューション、空港・海上廃棄物サービスなどの専門サービス、シャープスや使い捨てバイオハザード廃棄物容器、感染制御用品、シール＆センド薬物メールバックなどの医療用品店サービス、ステリセーフコンプライアンスソリューションなどのコンプライアンスソリューションを提供している。また、シュレッドイットブランドで文書、ハードドライブ、破壊サービスを含む安全な情報破壊サービスも提供している。同社は、病院、医療システム、非系列病院、国営および企業ヘルスケア、医院、手術センター、動物病院および歯科医院、看護および長期ケア施設、診療所および緊急ケア、透析センター、薬局、ラボ、研究センター、在宅医療機関などのヘルスケア事業、空港および港湾、教育機関、葬儀場および火葬場、政府および軍、銀行および専門サービス、その他の事業にサービスを提供している。ステリサイクル社は1989年に設立され、イリノイ州バノックバーンに本社を置いている。

Stericycle, Inc. 基礎のまとめ

Stericycle の収益と売上を時価総額と比較するとどうか。
SRCL 基礎統計学
時価総額US$5.75b
収益（TTM）US$20.20m
売上高(TTM)US$2.63b
284.9x
PER（株価収益率
2.2x
P/Sレシオ

SRCL は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
SRCL 損益計算書（TTM）
収益US$2.63b
売上原価US$1.63b
売上総利益US$1.00b
その他の費用US$980.10m
収益US$20.20m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）0.22
グロス・マージン38.08%
純利益率0.77%
有利子負債／自己資本比率53.1%

SRCL の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2024/11/04 06:41
終値2024/11/01 00:00
収益2024/09/30
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Stericycle, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21

アナリスト機関
Gary BisbeeBarclays
Alexander ParisBarrington Research Associates, Inc.
Kevin SteinkeBarrington Research Associates, Inc.